IP Library Granted Patent US 7,297,334
Granted Patent B2
US 7,297,334 · App. 10/974,591 · Granted Nov 20, 2007

Anti-vegf antibodies

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,297,334
App. No.
10/974,591
Granted
Nov 20, 2007
Kind
B2
Abstract

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.

Claims (9)

1. A method for inhibiting VEGF-induced angiogenesis in a subject, comprising administering to said subject an effective amount of a humanized anti-VEGF antibody which binds human VEGF with a K d value of no more than about 1×10 −8 M, said humanized anti-VEGF antibody having a heavy chain variable domain comprising the following heavy chain complementarity determining region (CDR) amino acid sequences: CDRH1(GYX 1 FTX 2 YGMN, wherein X 1 is T or D and X 2 is N or H; SEQ ID NO:128), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPX 1 YYGX 2 SHWYFDV, wherein X 1 is Y or H and X 2 is S or T; SEQ ID NO:129) and a light chain variable domain comprising the following light chain CDR amino acid sequences: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS; SEQ ID NO:5) and CDRL3 (QQYSTVPWT; SEQ ID NO:6).

2. The method of claim 1 wherein the heavy chain variable domain of said humanized anti-VEGF antibody comprises the amino acid sequence of SEQ ID NQ:7.

3. The method of claim 1 wherein the heavy chain variable domain of said humanized anti-VEGF antibody comprises the amino acid sequence of SEQ ID NO:116.

4. The method of claim 1 wherein the light chain variable domain of said humanized anti-VEGF antibody comprises the amino acid sequence of SEQ ID NO:8.

5. The method of claim 1 , wherein the light chain variable domain of said humanized anti-VEGF antibody comprises the amino acid sequence of SEQ ID NO:115.

6. The method of claim 1 , wherein said humanized anti-VEGF antibody is a full length antibody.

7. The method of claim 6 , wherein said humanized anti-VEGF antibody is a human IgG.

8. The method of claim 1 , wherein said humanized anti-VEGF antibody is an antigen-binding antibody fragment.

9. The method of claim 8 , wherein said humanized anti-VEGF antibody is a Fab.

Continuity (4)
Continuation 0972375200 · Nov 27, 2000
Division 0890846900 · Aug 6, 1997
Provisional Application 6012644600 · Apr 7, 1997
Related Publication 20050112126A1 · May 26, 2005